TBPH
Theravance Biopharma, Inc.
$16.64
+0.91%
$857.8M
No data for this timeframe.
Vol
Market Cap$857.8M
Cap SizeSmall Cap
Analyst ConsensusBuy (67%)
Insider Activity0B / 1S
Insider Net $-$108.1K
SEC Reports2
Recent Activity
May 20, 2026
Insider
Farnum Rhonda surrendered for taxes 5,678 shares
SVP, COMM & MEDICAL AFFAIRS @ $16.55 ($94.0K)
May 20, 2026
Insider
Grimaud Brett A. surrendered for taxes 8,829 shares
SVP, GEN COUNSEL AND SECRETARY @ $16.55 ($146.1K)
May 20, 2026
Insider
Miller Aine surrendered for taxes 6,827 shares
SVP, DEV & HEAD OF IRE OFFICE @ $16.55 ($113.0K)
May 7, 2026
SEC
Theravance Biopharma reported Q1 2026 revenue of $17.7M (+15% YoY), slightly above the $17.4M consensus, but GAAP EPS of
8-K — Impact 5/10
May 6, 2026
earnings_calendar
TBPH Q1 2026 Earnings Scheduled — 2026-05-06
Mar 3, 2026
SEC
Theravance Biopharma's Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint, prompting the compan
8-K — Impact 8/10
Price Targets
$17.40
+4.6% upside
Hold
Current $16.64
Low $15.00
Median $17.00
High $21.00
5 analysts
$15.00
$21.00
Analyst Ratings
3Strong Buy
5Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 7, 2026 | B. Riley Securities | MAINTAIN | Neutral → Neutral |
| Mar 23, 2026 | TD Cowen | MAINTAIN | Hold → Hold |
| Mar 20, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 5, 2026 | Oppenheimer | DOWNGRADE | Outperform → Perform |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.07 ▼ -69.6% | $0.07 — $0.07 | 183% YoY | 1 |
| Next Q | $0.20 ▼ -37.5% | $0.20 — $0.20 | 360% YoY | 1 |
| Current FY | $0.21 ▼ -94.1% | $0.21 — $0.21 | 242% YoY | 1 |
| Next FY | $1.25 ▼ -7.4% | $0.80 — $1.71 | 498% YoY | 2 |
Latest Reports
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 20, 2026 | Farnum Rhonda | F | $94.0K |
| May 20, 2026 | Grimaud Brett | F | $146.1K |
| May 20, 2026 | Miller Aine | F | $113.0K |
| May 20, 2026 | Sawaf Aziz | F | $143.5K |
| May 20, 2026 | Winningham Rick | F | $331.6K |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
5 unique insiders with 15 transactions. Net insider value: -$108.1K ($0.00 bought, $108.1K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | TAX W/H | 5,678 | $16.55 | $94.0K |
| May 20, 2026 | Grimaud Brett A. | SVP, GEN COUNSEL AND SECRETARY | TAX W/H | 8,829 | $16.55 | $146.1K |
| May 20, 2026 | Miller Aine | SVP, DEV & HEAD OF IRE OFFICE | TAX W/H | 6,827 | $16.55 | $113.0K |
| May 20, 2026 | Sawaf Aziz | SVP & CHIEF FINANCIAL OFFICER | TAX W/H | 8,670 | $16.55 | $143.5K |
| May 20, 2026 | Winningham Rick E | CHIEF EXECUTIVE OFFICER | TAX W/H | 20,038 | $16.55 | $331.6K |
| Apr 1, 2026 | Winningham Rick E | CHIEF EXECUTIVE OFFICER | AWARD | 75,000 | — | — |
| Apr 1, 2026 | Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | AWARD | 18,750 | — | — |
| Apr 1, 2026 | Grimaud Brett A. | SVP, GEN COUNSEL AND SECRETARY | AWARD | 37,500 | — | — |
| Apr 1, 2026 | Sawaf Aziz | SVP & CHIEF FINANCIAL OFFICER | AWARD | 37,500 | — | — |
| Mar 16, 2026 | Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | SELL | 7,767 | $13.92 | $108.1K |
| Feb 20, 2026 | Miller Aine | SVP, DEV & HEAD OF IRE OFFICE | TAX W/H | 16,851 | $19.66 | $331.3K |
| Feb 20, 2026 | Grimaud Brett A. | SVP, GEN COUNSEL AND SECRETARY | TAX W/H | 20,833 | $19.66 | $409.6K |
| Feb 20, 2026 | Sawaf Aziz | SVP & CHIEF FINANCIAL OFFICER | TAX W/H | 20,672 | $19.66 | $406.4K |
| Feb 20, 2026 | Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | TAX W/H | 13,929 | $19.66 | $273.8K |
| Feb 20, 2026 | Winningham Rick E | CHIEF EXECUTIVE OFFICER | TAX W/H | 74,975 | $19.66 | $1.5M |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 0 neutral. Avg impact: 6.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (67% buy). Based on 12 analysts: 3 strong buy, 5 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$17.40 mean target
+4.6% upside
Hold (3.00)
$15.00 Low
$21.00 High
| Metric | Value |
|---|---|
| Current Price | $16.64 |
| Target Low | $15.00 |
| Target Mean | $17.40 |
| Target Median | $17.00 |
| Target High | $21.00 |
| # Analysts | 5 |
| Recommendation | Hold (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.07 | $0.07 | $0.07 | 183.1% | -69.6% | — | $0.0B | -16.1% | 1 |
| Next Q 2026-09-30 |
$0.20 | $0.20 | $0.20 | 359.8% | -37.5% | — | $0.0B | 7.6% | 1 |
| Current FY 2026-12-31 |
$0.21 | $0.21 | $0.21 | 241.8% | -94.1% | — | $0.1B | -21.7% | 1 |
| Next FY 2027-12-31 |
$1.25 | $0.80 | $1.71 | 497.6% | -7.4% | 3↑ 0↓ | $0.1B | 15.1% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.070 | |
| 7d ago | $0.230 | -0.160 |
| 30d ago | $0.230 | -0.160 |
| 60d ago | $0.165 | -0.095 |
| 90d ago | $-0.025 | +0.095 |
5 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 7, 2026 | B. Riley Securities | MAINTAIN | Neutral | Neutral |
| Mar 23, 2026 | TD Cowen | MAINTAIN | Hold | Hold |
| Mar 20, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 5, 2026 | Oppenheimer | DOWNGRADE | Outperform | Perform |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | B. Riley Securities | DOWNGRADE | Buy | Neutral |
| Mar 3, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 3, 2026 | BTIG | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 4 | 0 | 0 | 67% | |
| May 1, 2026 | 3 | 5 | 4 | 0 | 0 | 67% | |
| Apr 1, 2026 | 3 | 5 | 5 | 0 | 0 | 62% | |
| Mar 1, 2026 | 4 | 6 | 3 | 0 | 0 | 77% | |
| Feb 1, 2026 | 4 | 6 | 3 | 0 | 0 | 77% | |
| Jan 1, 2026 | 4 | 6 | 3 | 0 | 0 | 77% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 23, 2026
Clinical Trial
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
Phase Phase 2 — COMPLETED
May 23, 2026
Clinical Trial
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation
Phase Phase 2 — COMPLETED
May 23, 2026
Clinical Trial
A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation
Phase Phase 2 — COMPLETED
May 23, 2026
Clinical Trial
A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation
Phase Phase 2 — COMPLETED
May 6, 2026
earnings_calendar
TBPH Q1 2026 Earnings Scheduled — 2026-05-06
Mar 26, 2026
short_interest
FTD: TBPH — 39,518 shares ($0.6M) failed to deliver
Settlement: 20260326, Price: $15.29, FTD Value: $604,230.22, THERAVANCE BIOPHARMA INC ORD S
Mar 2, 2026
earnings_calendar
TBPH Q4 2025 Earnings After Market Close — 2026-03-02